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INTRODUCTION
The localization in tissue of peptidoglycan-polysaccharide
(PG-PS) polymers derived from bacterial cell walls leads to
an acute inflammatory response which can evolve into a
remittent chronic inflammatory process with a prolonged
course (54). The PG-PS from several bacterial species,
including normal flora as well as pathogenic bacteria, can
induce such responses. The capacity to initiate and to
sustain a chronic destructive inflammation is dependent
upon resistance to biodegradation and consequent persis-
tence in tissue. The structural basis for resistance to host
muralytic enzymes, and other relevant biological properties,
form part of this review.
The target tissue and severity of disease in the various
experimental models described by ourselves and others depend
upon the immunocompetence of the host, the species and
genetic strain of animal, and route of injection (49). The
experimental chronic diseases induced by PG-PS include re-
mittent, nodular lesions of rabbit skin (41, 52); carditis in mice
resembling rheumatic carditis (11); synovitis in rabbit knee
joints (53, 64); granulomatous hepatitis in Lewis rats (71);
uveitis in rats (72); granulomatous enterocolitis in rats which
resembles Crohn's disease (47); intestinal hemorrhage in rats
(45); trilineage hemopoietic hyperplasia (21); and chronic,
remittent, erosive arthritis in rats (12). It is evident from this
summary that PG-PS can induce multisystem disease.
The preparation ofbacterial cell walls, isolation and fraction-
ation of PG-PS, injection of animals, and monitoring of disease
have been summarized in detail (68). Much of our work has
employed PG-PS isolated from the cell walls of group A
streptococci (Streptococcus pyogenes), which we label PG-
APS, but the arthropathogenic activities of numerous other
bacterial species also have been analyzed. The cellular and
molecular mechanisms of tissue injury and regulation of remis-
sion and recurrence in experimental models of arthritis and
intestinal inflammation have recently been reviewed (44, 51).
The balance of this review will examine the evidence that
PG-PS capable of inducing experimental arthritis and enteritis
can be identified in intestinal contents and be isolated from
pure cultures of normal-flora bacterial species and that it can be
systemically distributed to joints and other tissue.
RELEVANT STRUCTURAL AND BIOLOGICAL
PROPERTIES OF PG-PS
Properties of PG. PG and associated PS polymers of
bacterial cell walls are unique chemical structures which are
ubiquitous in our environment and have a broad range of
biological activities (9, 24). A basically similar PG structure
is present in almost all bacterial species, with important
differences in details of cross-linking and certain amino acid
components (24). PG can modulate the immune system (15,
50), and this is probably an important part of the pathogen-
esis of the experimental chronic inflammatory disorders
listed above (49). The PG-APS, which we have studied most
extensively, is toxic, immunogenic, and only slowly elimi-
nated from tissue (17, 41). The basis of the toxicity is due, in
part, to stimulation of secretion of interleukin-1, tumor
necrosis factor alpha, and other cytokines, as well as oxygen
radicals, nitric oxide, and eicosanoids, from a variety of
cells, including macrophages, granulocytes, and lympho-
cytes (51). PG-APS has a well-defined chemical structure
with at least four characterized immunodeterminant groups
on the PG (48) and two on the PS (10) moiety. The antibody
response of the rat to these epitopes on PG-APS has been
analyzed by Esser et al. (19). The PG was shown to be
immunogenic (1) and to be the primary toxic moiety (2). PG
shares many biological activities with endotoxin (9), and
both may use the same binding site on lymphocytes (16).
Numerous other biological properties of PG have been
described, including activation of the alternate and classical
complement pathways (18, 23) and activation of macro-
phages to become cytotoxic (60), to release lysosomal en-
zymes (14), and to resorb bone (4).
Many of these and other activities have been ascribed to
the muramyl dipeptide (N-acetyl-muramyl-L-alanyl-D-iso-
glutamine) structure of PG (6, 70); and certain analogs of
muramyl dipeptide were reported to induce polyarthritis in
rats (30). Aqueous suspensions of PG-PS or synthetic disac-
charide-dipeptide have also been reported to induce an acute
arthritis in certain inbred strains of mice (29). Fleming et al.
have shown that PG produced by Neisseria gonorrhoeae,
especially a lysozyme-resistant 0-acetylated form produced
by some strains, could be involved in gonococcal arthritis
(20). The gonococcal PG injected into Lewis rats in a
water-in-oil emulsion induced a severe synovitis with pannus
which progressed to erosion of cartilage and bone (61).
Properties of the PS and enzymatic degradation of PG-PS.
The PS moiety, covalently bound to the PG, modulates PG
activity and is essential for the capacity of PG-PS complexes
to persist and to induce chronic inflammation. The PS moiety
can be any PS which is covalently bound to PG, including
the ribitol teichoic acids. This excludes the capsular PSs.
The group A streptococcal polysaccharide (APS) component
of PG-APS is especially effective in protecting PG from
tissue muralytic enzymes, and it also masks the acute
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toxicity of PG, thereby permitting chronic irritation (2, 41).
The cell wall of group A streptococci and the isolated
PG-APS are very resistant to avian or mammalian lysozyme,
and this is the reason for the persistence of PG-APS in tissue
for prolonged periods (17, 22, 66). This extreme resistance of
PG-APS is largely due to the APS moiety, since PG-PS
polymers from many other bacteria, which differ in the
details of composition and structure of the PS, are more
susceptible to in vitro degradation by lysozyme. The relative
in vitro resistance to lysozyme correlates with their persis-
tence in tissue and their capacity to induce prolonged
chronic inflammation (65). Structural features of the PG are
also important determinants of lysozyme degradation, as
shown by the effect of N or 0 acylation on resistance to
lysozyme and arthropathic activity (67). Spitznagel et al. (63)
reported that treatment of cell walls from group A, B, or D
streptococci with lysozyme exposed different amounts of
amino sugar reducing groups on the PG, and this correlated
with alteration of complement activation by the PG. In
addition to lysozyme, other mammalian enzymes such as
serum N-acetylmuramyl-L-alanine amidase and endopepti-
dase can degrade isolated PG or MDP, but their significance
in "detoxification" or removal of PG-PS in vivo is uncertain
(22).
Although PG-APS is very resistant to mammalian and
avian lysozymes, it can be degraded in vitro by mutanolysin
(endo-N-acetylmuramidase) produced by Streptomyces glo-
bisporus or by group C streptococcal phage-associated lysin
(N-acetylmuramyl-L-alanine amidase) to fragments with Mrs
of less than 5 x 106, which cannot induce chronic erosive
arthritis (8). Mutanolysin can also function in vivo to prevent
or treat arthritis induced by PG-APS. A single intravenous
injection of 0.4 mg/kg protects against development of
chronic arthritis, even if treatment is delayed until arthritis is
established (25, 27). Part of the in vivo protective effect of
mutanolysin is due to the loss of complement activation by
PG-APS (26).
We have also shown that the purified APS has relevant
biological activity. This substance is able to induce rapid,
transient edema in the limbs of rats (7), and this is due to the
selective degranulation of mast cells in the limbs (13).
Low-molecular-weight PG-APS fragments derived by cleav-
age with muramidase enzymes, which are too small to
induce arthritis, can also induce early microvascular changes
and edema in rat limbs (8), but this is more prolonged than
the response elicited by PS and is not associated with mast
cell degranulation (13). Cell wall derivatives with this effect
on microvasculature could be a part of the pathogenesis of
experimental arthritis by influencing distribution of arthro-
pathic PG-APS fragments into synovial tissue or by effecting
expression of leukocyte adhesion molecules or secreted
mediators by endothelial cells (73).
ARTHROPATHOGENIC ACTIVITY OF INTACT CELLS
OR PG-PS FROM CELL WALLS OF NORMAL
BACTERIAL FLORA
As noted in the first description of bacterial cell wall-
induced arthritis, cell wall fragments from some bacterial
species other than group A streptococci can also induce
acute arthritis following systemic injection, and with some of
these the disease progresses into a chronic, erosive synovitis
(12). These species include beta-hemolytic streptococci of
groups B, C, and H. It is important that intact heat-killed
group A and group B cells, at equivalent doses of cell wall
rhamnose, could also induce chronic arthritis, but in the case
of group A streptococci, only after a lag time of 56 to 120
days after intraperitoneal injection (12, 62). Stimpson et al.
(65, 69) showed that PG-PS isolated from group D strepto-
cocci (Streptococcus faecium) and Peptostreptococcus pro-
ductus, both normal-flora species, could also induce chronic
arthritis, whereas PG-PS from Propionibacterium acnes and
the pseudomurein-PS complex isolated from Methanobacte-
rium formicium could not. However, PG-PS from group D
streptococci could only induce both acute and chronic
phases of the arthritis if care was taken to stabilize it by
heating and extracting with detergent to eliminate autolytic
enzyme activity (65). This is consistent with the concept that
prolonged inflammation requires persistence of PG-PS,
which in turn is dependent upon resistance to muralytic
enzymes, either host lysozyme or microbial autolytic en-
zymes (22, 53). Cell wall fragments from some Lactobacillus
species can also induce chronic inflammation (33).
In our experience, cell wall fragments from group A
streptococci produce the most impressive chronic recurrent
erosive arthritis, and disease remains active for at least 4
months after intraperitoneal injection. Disease induced with
material from most other species, although often severe,
subsides after 2 to 3 months (65). We have associated this
with in vitro susceptibility to lysozyme and persistence in
tissue (66, 67), but others have reported that this association
of in vitro resistance to lysozyme and severe chronic arthri-
tis is not seen with the strict anaerobes Eubacterium aero-
faciens and Coprococcus ramosum (57). In a series of
studies Severijnen and coworkers showed that arthropathic
cell walls could be isolated from two strains of Eubacterium
contortum, which are gram-positive anaerobic organisms
that are prominent in the stools of patients with Crohn's
disease (56). Arthropathic cell wall fragments were also
isolated from anaerobic species common in the normal
human intestine (58, 59), including E. aerofaciens and
Bifidobacterium sp., but not from some other Eubacterium
or Clostridium species examined (56). However, cell walls
isolated from species of autochthonous intestinal flora of
rats, which had resemblance to human strains of E. aero-
faciens, did not induce chronic arthritis upon intraperitoneal
injection (32).
ASSOCIATION OF INTESTINAL INFLAMMATION,
SYSTEMIC DISTRIBUTION OF PG-PS, AND
INFlAMMATION OF JOINTS AND LIVER
It is evident that arthropathogenic PG-PS polymers can be
derived from the cell walls of a variety of bacteria, including
many species making up the normal flora (58, 59), as well as
bacteria which occur in increased numbers in the intestines
of rheumatoid arthritis patients (57) and patients with
Crohn's disease (56). The well-established association be-
tween arthritis and intestinal inflammation (43) has stimu-
lated efforts to determine if, in fact, potentially arthropatho-
genic PG-PS products of bacterial degradation exist in the
intestinal lumen and if they are systemically translocated to
tissues such as the joints and liver. Kool et al. (31) have
demonstrated that PG-PS complexes can be isolated from
the feces of healthy humans and from ileostomy fluid.
Material from an ileostomy fluid, but not that isolated from
feces, could induce arthritis when injected subcutaneously in
incomplete Freund's adjuvant. However, it is difficult for
such studies to be definitive since much of the PG-PS in the
intestine must be nonarthropathogenic because of properties
related to structure or fragment size (59, 65), and this would
greatly increase the dose of total cell wall required in order
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to be effective. As a further complication, we have shown
that the presence of relatively small (Mr of < 104) nonarthro-
pathogenic, enzyme-degraded PG-PS fragments can sup-
press development of arthritis (69).
Sartor and coworkers (46) have demonstrated that arthro-
pathogenic, 125I-labeled PG-APS fragments injected into rat
cecum which had been inflamed with acetic acid could be
detected in the liver, spleen, and mesenteric lymph nodes. In
parallel assays, APS antigen, which is not found in the rat
microbial flora, was also measured in the same tissues by
enzyme-linked immunosorbent assay.
In another approach, jejunal self-filling blind loops, which
cause small bowel bacterial overgrowth with very elevated
numbers of anaerobic bacteria, were surgically created in
rats (35). With this model, indirect evidence for the translo-
cation of PG across the intestinal wall was provided by the
increased level of anti-PG antibodies in the sera of rats with
self-filling blind loops compared with that in sham-operated
control rats or rats treated with metronidazole. In addition,
following intraluminal injection of the inflamed loop with
PG-APS, the APS antigen could be detected in the plasma
and liver (35). Related studies also showed that circulating
PG-PS can be eliminated in the bile (38). Evidence that the
hepatobiliary injury that occurs in rats with small bowel
bacterial overgrowth is initiated by PG-PS is provided by the
protection of these animals by intravenous injection of
mutanolysin, an enzyme whose only known activity is
degradation of PG (37). About 50% of the PG-PS transported
to the liver is localized in Kupffer cells, with the rest in
parenchymal and endothelial cells (36). Evidence that PG-PS
stored in the liver retains arthropathogenic activity and
could provide a depot for induction of recurrent arthritis
comes from experiments showing that transplantation of
PG-PS-laden livers can cause reactivation of monoarticular
arthritis in recipient rats that had been injected intra-articu-
larly with PG-APS (34).
The significance of these findings for human disease is
indicated by the serological evidence that immunoglobulin G
and M antibodies to PG are elevated in sera of rheumatoid
arthritis and juvenile rheumatoid arthritis patients (5, 28, 39,
40, 42), suggesting that immunogenic bacterial PG com-
plexes can be systemically translocated in humans. That this
may be related to transient or chronic changes in the
mucosal barrier is indicated by studies summarized by
Sartor (43). Bjamason et al. (3) reported that two-thirds of
rheumatoid arthritis patients have ileocecal inflammation;
and although he associated this with mucosal injury caused
by nonsteroidal anti-inflammatory drugs, others have pro-
posed a primary relationship of intestinal inflammation
and rheumatoid arthritis (55).
SUMMARY
PG-PS polymers which can induce experimental chronic
inflammation in joints and other tissues can be isolated from
the cell walls of human pathogens, such as group A strepto-
cocci, as well as from certain indigenous bacterial species
which colonize the human intestinal tract. The structural and
biological properties that are required for cell wall fragments
to express this remarkable activity are still not well defined,
but polymer size, resistance to tissue enzymes, and capacity
to sustain activation of complement, macrophages, neutro-
phils, and T cells are properties associated with the most
active preparations. There is increasing evidence that PG-PS
structures with arthropathogenic activity occur in the human
intestinal lumen and that these polymers can be translocated
systemically. These observations support the concept that
PG-PS, derived from a variety of bacterial species, can be
part of the etiology of rheumatoid arthritis and other chronic
inflammatory diseases. Since the PG component provides a
common element to which all individuals are exposed, it
follows that susceptibility is related to efficiency of disposal
of bacterial cell wall debris, as well as to cytokine networks
and immune cell function (51).
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